著者

山本 明子

出版者

公益社団法人 日本薬学会

雑誌

ファルマシア (ISSN:00148601)

巻号頁・発行日

vol.50, no.10, pp.949_1, 2014

---

この原稿の締め切りの1週間前にいわゆる会社の女子会があり,そこで「山本さんの目標とする人とかロールモデルってどなたでしたか?」と質問され,答えに窮した.私自身これまであまり意識したことがなかったからだ.ロールモデルは,社員が将来目指したいと思う模範となる存在で,そのスキルや具体的な行動を学んだり模倣をしたりする対象となる人材のこと.ロールモデルの必要性は,女性活用推進のアクション・プランなどで指摘されていて,企業におけるロールモデルの育成など,普及のための様々な取り組みが行われている.ロールモデルは一人とは限らなくて,社内にいなければ社外でもいいし,同性でなくてもよいそうだ.

著者

石黒 洋 山本 明子 中莖 みゆき 衣 蘭娟 石黒 真理子 山口 誠 近藤 志保 持丸 由香 Ishiguro Hiroshi Yamamoto Akiko Nakakuki Miyuki Yi Lanjuan Ishiguro Mariko Yamaguchi Makoto Kondo Shiho Mochimaru Yuka

出版者

名古屋大学総合保健体育科学センター

雑誌

総合保健体育科学 (ISSN:02895412)

巻号頁・発行日

vol.35, no.1, pp.9-15, 2012-03-30

---

Excretion of hypotonic sweat by eccrine sweat gland is achieved by re-absorption of NaCl by sweat duct which is an important function to prevent the salt loss and heat prostration. The Cl– transport by sweat duct is mediated by cystic fibrosis transmembrane conductance regulator (CFTR) anion channel. CFTR is the causative gene for cystic fibrosis, an autosomal recessive genetic disease. CFTR functions as a cAMP-dependent anion channel localized in the apical membrane of various epithelia. Loss of function due to severe mutations in both alleles causes typical cystic fibrosis characterized by dehydrated, thick, and viscous luminal fluid/mucus in the respiratory and gastrointestinal tract, pancreatic duct, and vas deferens. Cystic fibrosis is the most common genetic disease in Caucasians (1 per ~3,000 births) but it is rare in the Asian population including Japanese (1 per ~1.5 million). A compound heterozygote of mutations/polymorphisms (causing a mild dysfunction of CFTR) involves a risk of developing CFTR-related diseases (or atypical cystic fibrosis) such as chronic pancreatitis and male infertility due to congenital bilateral absence of the vas deferens (CBAVD). Recent studies suggest that CFTR mutations/polymorphisms are frequently found in Japanese patients with chronic pancreatitis, CBAVD and diffuse panbronchiolitis. Cl– concentration in the sweat is a useful measure of CFTR function in human. The sweat [Cl–] in healthy subjects is correlated with ages. High levels (>60 mM) of sweat [Cl–] suggest the dysfunction of CFTR.

著者

脇坂 真美 宋 一大 田ヶ谷 浩邦 藤田 朋恵 前田 実花 野村 今日子 小林 真美 山本 明子 坂本 泰理 田中 理英子 熊谷 雄治

出版者

一般社団法人 日本臨床薬理学会

雑誌

臨床薬理 (ISSN:03881601)

巻号頁・発行日

vol.46, no.5, pp.243-248, 2015-09-30 (Released:2016-01-15)

参考文献数

15

---

The aim of the present trial was to compare the sedative effects of second generation antihistamines in healthy adult male volunteers. This randomized, double-blind, cross-over clinical trial compared the effects of single doses of olopatadine 5 mg, ketotifen fumarate 1.38 mg, fexofenadine 60 mg, and placebo on psychomotor function in 15 healthy male subjects who gave written informed consent for participation in the study. For each sedative, sleep latency time was measured using the multiple sleep latency test (MSLT); and psychomotor function was measured by thresholds of critical flicker fusion (CFF), the digit symbol substitution test (DSST), and a Straight line Analog Rating Scale (LARS). Measurements were performed before and 2, 5, and 8h after drug administration. The differences between the drugs and placebo were analyzed by repeated analysis of variance (ANOVA) and paired t-tests as appropriate. Intergroup differences in baseline values of all parameters were not significant. Ketotifen induced the shortest sleep latency at 2h (p=0.03 vs. fexofenadine, p=0.03 vs. olopatadine) and 5h (p=0.04 vs. fexofenadine) after administration. Ketotifen also showed the most prolonged recognition (CFF down) at 2h (p<0.001 vs. fexofenadine, p=0.03 vs. olopatadine) and 8h (p=0.01 vs. fexofenadine). Olopatadine showed a more prolonged recognition than fexofenadine at 2h (p=0.03). Ketotifen induced the greatest decline in concentration and cognitive function at 8h (p=0.03) according to DSST. The drugs affected objective psychomotor function without causing subjective symptoms as shown by no significant differences in LARS score. The study indicates that the extent of impaired performance, an important adverse drug reaction, may differ even among second generation antihistamines.